MEI Pharma (MEIP) PT Lowered to $3 at Truist Securities on zandelisib Delay, but Maintains Conviction in Drug, Sees Peak Sales of $94M
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas lowered the price target on MEI Pharma (NASDAQ: MEIP) to $3.00 (from $8.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
